Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer

This is a multi-center, open label, Phase 1b study of NXP900 in combination with osimertinib in subjects with advanced, progressing, EGFR-mutated non-small cell lung cancer (NSCLC)

Trial Details

NCT ID

NCT07315113

Phase

PHASE1

Sponsor

Nuvectis Pharma, Inc.

Status

RECRUITING

Cancer Type

Non-Small Cell (NSCLC) Lung Cancer

Interventions

NXP900
Osimertinib

Locations (sample)

Boston, Massachusetts, United States|42.35843,-71.05977
Houston, Texas, United States|29.76328,-95.36327
Fairfax, Virginia, United States|38.84622,-77.30637

Key Eligibility Criteria

Provide written informed consent.
18 years old or older.
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
Unresectable, metastatic or locally advanced EGFR-mutated NSCLC.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →